PCSK9抑制剂对急性冠脉综合征的研究进展

摘要/Abstract

摘要： 动脉粥样硬化性心血管疾病（ASCVD）发病率逐年上升,发病机制与粥样硬化斑块相关,而低密度脂蛋白胆固醇（LDL-C）是关键诱发因素,因此积极降LDL-C、稳定粥样斑块、减少主要不良心血管事件（MACE）发生是临床工作防治的重点。尽管积极使用他汀降脂,仍有部分患者血脂未达标、发生MACE,甚至对他汀不耐受,因此迫切需要降脂的替代治疗。前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂是新型降脂药,通过增加低密度脂蛋白胆固醇受体（LDLR）的循环利用,显著降低LDL-C水平。众多临床实验已经证明其良好的安全性和耐受性,本文就PCSK9与疾病的关系及PCSK9抑制剂的临床进展作一综述。

关键词: 急性冠脉综合征, 低密度脂蛋白胆固醇, 动脉粥样硬化性心血管疾病, PCSK9抑制剂

宋来青, 李强. PCSK9抑制剂对急性冠脉综合征的研究进展[J]. 心血管病防治知识, 2025, 15(13): 141-144.

参考文献

[1] Katrin G,Holger R .PCSK9 inhibition for LDL lowering and beyond-implications for patients with peripheral artery disease.[J].VASA. Zeitschrift fur Gefasskrankheiten,2018,47(3):165-176.
[2] 国家心血管病专家委员会联合中华医学会心血管病学分会、内分泌学分会、糖尿病学分会、检验医学分会和中国卒中学会组成的中国血脂管理指南修订联合专家委员会修订.中国血脂管理指南(2023年)[J].中国循环杂志. 2023,38(3):237-271.
[3] A B F,N H G,Ian G , et al.Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.[J].European heart journal,2017,38(32):2459-2472.
[4] Vogel A R .PCSK9 Inhibition[J].Journal of the American College of Cardiology,2012,59(25):2354-2355.
[5] Hagai T,Daping F,L J B , et al.Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.[J].Circulation,2013,127(24):2403-13.
[6] S M S,P R G,C A K, et al.Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.[J].The New England journal of medicine,2017,376(18):1713-1722.
[7] Koskinas C K,Windecker S,Pedrazzini G, et al.Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)[J].Journal of the American College of Cardiology,2019,74(20):2452-2462.
[8] G G S,Gabriel P S ,Michael S , et al.Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.[J].The New England journal of medicine,2018,379(22):2097-2107.
[9] Litong Q,Dexue L,Yanling Q, et al.Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial[J].JACC: Asia,2023,3(4):636-645.
[10] W K,K K R,G D K, et al.Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials[J].European Heart Journal,2021,42(Supplement1):
[11] 霍勇,李勇,韩雅君,等.英克司兰治疗亚洲动脉粥样硬化性心血管疾病患者或高危人群的疗效与安全性:ORION-18研究中国大陆亚组分析[J].中国循环杂志,2025,40(2):124-130.
[12] Nicholls J S,Puri R,Anderson T, et al.Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial[J].JAMA,2016,316(22):2373-2384.
[13] J. S N,Yu K ,E. S N , et al.Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction[J].JACC: Cardiovascular Imaging,2022,15(7):1308-1321.
[14] Lorenz R,Yasushi U,Tatsuhiko O, et al.Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.[J].JAMA,2022,327(18):
[15] Chunteng J,Santuan X,Guang Y, et al.Spotlight on NLRP3 Inflammasome: Role in Pathogenesis and Therapies of Atherosclerosis.[J].Journal of inflammation research,2021,147143-7172.
[16] Zufeng D,K V N P ,Akshay G , et al.PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1.[J].Cardiovascular research,2020,116(5):908-915.
[17] M P R,M B E,Tom T , et al.Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.[J].The New England journal of medicine,2017,377(12):1119-1131.
[18] Can I,R P M ,Trung N , et al.THE ENDOTHELIUM IN SEPSIS.[J].Shock (Augusta, Ga.),2016,45(3):259-70.
[19] J S,L B,S B, et al.Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function.[J].Microvascular research,2023,148104513-104513.
[20] Dennis K,Agnes B,Kristina S, et al.Abstract 13958: Evolocumab Alters Vascular Function in Patients With Cardiovascular Disease[J].Circulation,2022,146(Suppl_1):A13958-A13958.
[21] José T,Gabriel P S,L D B , et al.Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.[J].European heart journal,2020,41(42):4114-4123.
[22] Bittner A V,Szarek M,Aylward E P, et al.Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome[J].Journal of the American College of Cardiology,2020,75(2):133-144.
[23] Sabatine S M,Leiter A L,Wiviott D S, et al.Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial[J].The Lancet Diabetes & Endocrinology,2017,5(12):941-950.
[24] P R G,S M S,R B O .Cognitive Function in a Randomized Trial of Evolocumab.[J].The New England journal of medicine,2017,377(20):1997.
[25] Jose S,José M M,Pedro S, et al.Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World-MEMOGAL Study.[J].American journal of cardiovascular drugs : drugs, devices, and other interventions,2023,23(5):583-593.